GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 3067L
GlaxoSmithKline PLC
17 July 2017
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

1,497.674

£16.18

776.283

£16.18

2,556.747

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

4,830.704

£16.18

 

 

 

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

1,165.640

£16.18

1,492.989

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,658.629

£16.18

 

  

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

298.166

£16.18

375.805

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

673.971

£16.18

 

 

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

   

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

2,535.105

£16.18

2,745.620

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

5,280.725

£16.18

 

  

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

565.161

£16.18

615.859

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,181.020

£16.18

 

 

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

2,649.200

£16.18

2,985.991

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

5,635.191

£16.18

 

 

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

  

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

927.212

£16.18

1,082.411

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,009.623

£16.18

 

 

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, HR

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

1,236.288

£16.18

1,362.348

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,598.636

£16.18

 

 

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

  

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

715.284

£16.18

783.821

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,499.105

£16.18

 

  

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

       

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

2,571.481

£16.18

3,172.607

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

5,744.088

£16.18 

  

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

  

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£16.18

158.334

£16.18

149.637

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

307.971

£16.18

 

e)

Date of the transaction

2017-07-14

f)

Place of the transaction

 

n/a

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHDDLFFDDFBBBQ